Cardiff Oncology
CRDF
90 hedge funds and large institutions have $176M invested in Cardiff Oncology in 2021 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 23 increasing their positions, 24 reducing their positions, and 15 closing their positions.
113% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 15
23% more funds holding
Funds holding: 73 → 90 (+17)
5.65% more ownership
Funds ownership: 64.99% → 70.64% (+5.7%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 24
10% less call options, than puts
Call options by funds: $2.11M | Put options by funds: $2.35M
21% less capital invested
Capital invested by funds: $223M → $176M (-$46.7M)
Top Buyers
| 1 |
BlackRock
New York
|
+$15.5M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$15.2M |
| 3 |
ACM
Altium Capital Management
New York
|
+$4.26M |
| 4 |
State Street
Boston,
Massachusetts
|
+$4.1M |
| 5 |
Morgan Stanley
New York
|
+$3.75M |
Top Sellers
| 1 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$11.9M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$8.93M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$5.39M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$4.83M |
| 5 |
Millennium Management
New York
|
-$2.99M |
CRDF Hedge Fund Activity: Q2 2021 in Review
90 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q2 2021, worth a combined $176M — down 21% from $223M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new CRDF positions and 15 closed out — a net gain of 17 holders — while 23 added to existing stakes and 24 trimmed.
The largest buyer was BlackRock, adding an estimated $15.5M. The largest seller was Corriente Advisors, cutting an estimated $11.9M.
- 90 institutional investors held Cardiff Oncology (CRDF) as of Q2 2021, up from 73 in Q1 2021.
- Funds reported $176M of Cardiff Oncology stock for Q2 2021, down 21% quarter-over-quarter.
- 32 funds opened new Cardiff Oncology positions in Q2 2021 and 15 closed out, a net change of +17 holders.
- The largest Cardiff Oncology buyer in Q2 2021 was BlackRock, an estimated $15.5M added.
- The largest Cardiff Oncology seller in Q2 2021 was Corriente Advisors, an estimated $11.9M sold.
Based on aggregated 13F filings for Q2 2021.